



Minerva Neurosciences, Inc.  
Investor Relations Department  
1601 Trapelo Road  
Suite 284  
Waltham, MA 02451  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: NERV

Last Trade:	8.20
Trade Time:	4:00 PM ET Jul 20, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	6.50 - 14.92
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat central nervous system (CNS) diseases. Minerva's proprietary compounds include: MIN-101, which has completed Phase IIb development for schizophrenia; MIN-202 (JNJ-42847922), which has completed Phase IIa and Phase Ib clinical trials for insomnia and MDD, respectively; MIN-117, which has completed Phase IIa development for MDD; and MIN-301, in pre-clinical development for Parkinson's disease. Minerva's common stock is... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Jul 5, 2017*  
[Minerva Neurosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares](#)
- Jun 28, 2017*  
[Minerva Neurosciences Announces Pricing of Public Offering of Common Stock](#)
- Jun 27, 2017*  
[Minerva Neurosciences, Inc. to Offer Common Shares](#)
- Jun 22, 2017*  
[Minerva Announces Completion of Bridging Study to Select Improved Formulation of MIN-101 for Use in Phase 3 Trial for the Treatment of Negative Symptoms in Patients With Schizophrenia](#)
- May 31, 2017*  
[Minerva Announces Amended Agreement for MIN-202 in Insomnia](#)

## Financials [\[ View all \]](#)

- [First Quarter Financial Results](#)
- Mar 13, 2017*  
[Annual Report \(10-K\)](#)
- Apr 18, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- May 4, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016*  
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2016*  
[Quarterly Report \(10-Q\)](#)